Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2020

Primary Completion Date

August 31, 2022

Study Completion Date

November 30, 2022

Conditions
Type 2 DiabetesCardiovascular Diseases
Interventions
DRUG

Liraglutide Pen Injector [Victoza]

Increasing dose of Liraglutide: 0.6 mg/d for the first week, 1.2 mg/d for the second week aiming for a maximum of 1.8 mg/d beginning with the third week (or highest tolerated dose).Subcutaneous injection once daily via pre-filled pen

DRUG

Placebo

Matching Placebo once daily, subcutaneous injection via pre-filled pen.

Trial Locations (1)

52074

Department of Internal Medicine I, University Hospital, Aachen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

RWTH Aachen University

OTHER

NCT04057261 - Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease | Biotech Hunter | Biotech Hunter